Summer Street Starts Ligand Pharma (LGND) at Buy, Sets $22 Price Target
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $72.06 -0.63%
Rating Summary:
9 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Rating Summary:
9 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Join SI Premium – FREE
Shares of Ligand Pharma (NASDAQ: LGND) are pushing lower Friday morning despite a new Buy rating from an analyst at Summer Street. The firm set a $22 price target on the stock.
With shares down 1 percent to $11.84 at last check, Summer Street's new price target implies potential upside of about 86 percent.
For an analyst ratings summary and ratings history on Ligand Pharma click here. For more ratings news on Ligand Pharma click here.
With shares down 1 percent to $11.84 at last check, Summer Street's new price target implies potential upside of about 86 percent.
For an analyst ratings summary and ratings history on Ligand Pharma click here. For more ratings news on Ligand Pharma click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TD Cowen Resumes EQT Corp. (EQT) at Hold
- Craig-Hallum Assumes Alimera Sciences (ALIM) at Buy
- Truist Securities Starts Delek Logistics Partners, LP (DKL) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
